A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice

S. Barni, V. Lorusso, M. Giordano, G. Sogno, T. Gamucci, A. Santoro, R. Passalacqua, V. Iaffaioli, N. Zilembo, M. Mencoboni, M. Roselli, G. Pappagallo, P. Pronzato

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines recommend primary prophylaxis with G-CSF in patients with an overall ≥20 % risk of FN. AIOM Italian guidelines recommend starting G-CSF within 24-72 h after chemotherapy; for daily G-CSF, administration should continue until the absolute neutrophil count (ANC) is 1 × 109/L post-nadir and should not be terminated after ANC increase in the early days of administration. The aim of this study was to assess guideline adherence in oncology practice in Italy. In this multicenter, prospective, observational study, patients were enrolled at the first G-CSF use in any cycle and were followed for two subsequent cycles (or until the end of chemotherapy if less than two additional cycles). Primary objective was to explore G-CSF use in Italian clinical practice; therefore, data were collected on the G-CSF type, timing of administration, and number of doses. 512 eligible patients were enrolled (median age, 62). The most common tumor types were breast (36 %), lung (18 %), and colorectal (13 %). A total of 1,164 G-CSF cycles (daily G-CSF, 718; pegfilgrastim, 446) were observed. Daily G-CSF was administered later than 72 h after chemotherapy in 42 % of cycles, and the median [range] number of doses was four [1, 10]. Pegfilgrastim was administered later than 72 h in 8 % of cycles. G-CSF prophylaxis in Italy is frequently administered in a manner which is not supported by evidence-based guidelines. As this practice may lead to poor outcomes, educational initiatives are recommended.

Original languageEnglish
Article number797
JournalMedical Oncology
Volume31
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Medical Oncology
Granulocyte Colony-Stimulating Factor
Observational Studies
Prospective Studies
Drug Therapy
Neoplasms
Febrile Neutropenia
Italy
Neutrophils
Guidelines
Guideline Adherence
Practice Guidelines
Breast Neoplasms
Lung

Keywords

  • G-CSF
  • Guidelines
  • Italy
  • Observational study
  • Oncology practice
  • Solid tumors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. / Barni, S.; Lorusso, V.; Giordano, M.; Sogno, G.; Gamucci, T.; Santoro, A.; Passalacqua, R.; Iaffaioli, V.; Zilembo, N.; Mencoboni, M.; Roselli, M.; Pappagallo, G.; Pronzato, P.

In: Medical Oncology, Vol. 31, No. 1, 797, 2014.

Research output: Contribution to journalArticle

Barni, S. ; Lorusso, V. ; Giordano, M. ; Sogno, G. ; Gamucci, T. ; Santoro, A. ; Passalacqua, R. ; Iaffaioli, V. ; Zilembo, N. ; Mencoboni, M. ; Roselli, M. ; Pappagallo, G. ; Pronzato, P. / A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. In: Medical Oncology. 2014 ; Vol. 31, No. 1.
@article{e2a0f63c334a4b2fa5c28b1919a21359,
title = "A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice",
abstract = "Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines recommend primary prophylaxis with G-CSF in patients with an overall ≥20 {\%} risk of FN. AIOM Italian guidelines recommend starting G-CSF within 24-72 h after chemotherapy; for daily G-CSF, administration should continue until the absolute neutrophil count (ANC) is 1 × 109/L post-nadir and should not be terminated after ANC increase in the early days of administration. The aim of this study was to assess guideline adherence in oncology practice in Italy. In this multicenter, prospective, observational study, patients were enrolled at the first G-CSF use in any cycle and were followed for two subsequent cycles (or until the end of chemotherapy if less than two additional cycles). Primary objective was to explore G-CSF use in Italian clinical practice; therefore, data were collected on the G-CSF type, timing of administration, and number of doses. 512 eligible patients were enrolled (median age, 62). The most common tumor types were breast (36 {\%}), lung (18 {\%}), and colorectal (13 {\%}). A total of 1,164 G-CSF cycles (daily G-CSF, 718; pegfilgrastim, 446) were observed. Daily G-CSF was administered later than 72 h after chemotherapy in 42 {\%} of cycles, and the median [range] number of doses was four [1, 10]. Pegfilgrastim was administered later than 72 h in 8 {\%} of cycles. G-CSF prophylaxis in Italy is frequently administered in a manner which is not supported by evidence-based guidelines. As this practice may lead to poor outcomes, educational initiatives are recommended.",
keywords = "G-CSF, Guidelines, Italy, Observational study, Oncology practice, Solid tumors",
author = "S. Barni and V. Lorusso and M. Giordano and G. Sogno and T. Gamucci and A. Santoro and R. Passalacqua and V. Iaffaioli and N. Zilembo and M. Mencoboni and M. Roselli and G. Pappagallo and P. Pronzato",
year = "2014",
doi = "10.1007/s12032-013-0797-z",
language = "English",
volume = "31",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "1",

}

TY - JOUR

T1 - A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice

AU - Barni, S.

AU - Lorusso, V.

AU - Giordano, M.

AU - Sogno, G.

AU - Gamucci, T.

AU - Santoro, A.

AU - Passalacqua, R.

AU - Iaffaioli, V.

AU - Zilembo, N.

AU - Mencoboni, M.

AU - Roselli, M.

AU - Pappagallo, G.

AU - Pronzato, P.

PY - 2014

Y1 - 2014

N2 - Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines recommend primary prophylaxis with G-CSF in patients with an overall ≥20 % risk of FN. AIOM Italian guidelines recommend starting G-CSF within 24-72 h after chemotherapy; for daily G-CSF, administration should continue until the absolute neutrophil count (ANC) is 1 × 109/L post-nadir and should not be terminated after ANC increase in the early days of administration. The aim of this study was to assess guideline adherence in oncology practice in Italy. In this multicenter, prospective, observational study, patients were enrolled at the first G-CSF use in any cycle and were followed for two subsequent cycles (or until the end of chemotherapy if less than two additional cycles). Primary objective was to explore G-CSF use in Italian clinical practice; therefore, data were collected on the G-CSF type, timing of administration, and number of doses. 512 eligible patients were enrolled (median age, 62). The most common tumor types were breast (36 %), lung (18 %), and colorectal (13 %). A total of 1,164 G-CSF cycles (daily G-CSF, 718; pegfilgrastim, 446) were observed. Daily G-CSF was administered later than 72 h after chemotherapy in 42 % of cycles, and the median [range] number of doses was four [1, 10]. Pegfilgrastim was administered later than 72 h in 8 % of cycles. G-CSF prophylaxis in Italy is frequently administered in a manner which is not supported by evidence-based guidelines. As this practice may lead to poor outcomes, educational initiatives are recommended.

AB - Febrile neutropenia (FN) is a severe dose-limiting side effect of myelosuppressive chemotherapy in patients with solid tumors. Clinical practice guidelines recommend primary prophylaxis with G-CSF in patients with an overall ≥20 % risk of FN. AIOM Italian guidelines recommend starting G-CSF within 24-72 h after chemotherapy; for daily G-CSF, administration should continue until the absolute neutrophil count (ANC) is 1 × 109/L post-nadir and should not be terminated after ANC increase in the early days of administration. The aim of this study was to assess guideline adherence in oncology practice in Italy. In this multicenter, prospective, observational study, patients were enrolled at the first G-CSF use in any cycle and were followed for two subsequent cycles (or until the end of chemotherapy if less than two additional cycles). Primary objective was to explore G-CSF use in Italian clinical practice; therefore, data were collected on the G-CSF type, timing of administration, and number of doses. 512 eligible patients were enrolled (median age, 62). The most common tumor types were breast (36 %), lung (18 %), and colorectal (13 %). A total of 1,164 G-CSF cycles (daily G-CSF, 718; pegfilgrastim, 446) were observed. Daily G-CSF was administered later than 72 h after chemotherapy in 42 % of cycles, and the median [range] number of doses was four [1, 10]. Pegfilgrastim was administered later than 72 h in 8 % of cycles. G-CSF prophylaxis in Italy is frequently administered in a manner which is not supported by evidence-based guidelines. As this practice may lead to poor outcomes, educational initiatives are recommended.

KW - G-CSF

KW - Guidelines

KW - Italy

KW - Observational study

KW - Oncology practice

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=84888786744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888786744&partnerID=8YFLogxK

U2 - 10.1007/s12032-013-0797-z

DO - 10.1007/s12032-013-0797-z

M3 - Article

C2 - 24307348

AN - SCOPUS:84888786744

VL - 31

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 1

M1 - 797

ER -